← Back to Search

Tetracycline Antibiotic

BPX-04 Active for Papulopustular Rosacea (PRISM Trial)

Phase 2
Waitlist Available
Research Sponsored by BioPharmX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights
All Individual Drugs Already Approved

Summary

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Eligible Conditions
  • Papulopustular Rosacea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Inflammatory lesion count
Secondary study objectives
Change in IGA

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BPX-04 ActiveExperimental Treatment1 Intervention
BPX-04 1% minocycline topical gel
Group II: BPX-04 VehiclePlacebo Group1 Intervention
BPX-04 topical gel vehicle

Find a Location

Who is running the clinical trial?

BioPharmX, Inc.Lead Sponsor
6 Previous Clinical Trials
351 Total Patients Enrolled
AnnaMarie DanielsStudy DirectorBioPharmX, Inc.
4 Previous Clinical Trials
315 Total Patients Enrolled
~29 spots leftby Nov 2025